The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories's revenues will grow 2.3% and EPS will grow 3.4%.
The average estimate for revenue is $10.62 billion. On the bottom line, the average EPS estimate is $1.50.
Last quarter, Abbott Laboratories booked revenue of $9.77 billion. GAAP reported sales were 0.4% lower than the prior-year quarter's $9.82 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.30. GAAP EPS of $1.21 for Q3 were much higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 62.9%, 340 basis points better than the prior-year quarter. Operating margin was 23.8%, 250 basis points better than the prior-year quarter. Net margin was 19.9%, 1,680 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $39.72 billion. The average EPS estimate is $5.05.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,542 members out of 2,632 rating the stock outperform, and 90 members rating it underperform. Among 654 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 637 give Abbott Laboratories a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is hold, with an average price target of $68.14.
Is Abbott Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.